Moxonidin Ratiopharm (Moxonidine)

Moxonidine acts as a selective agonist at central imidazoline I1 receptors. Stimulation of these receptors reduces sympathetic nervous system outflow, leading to decreased peripheral vascular resistance and cardiac output, which together lower arterial blood pressure.

The appropriate dose of Moxonidin Ratiopharm is determined by the prescribing clinician based on the individual patient's condition, response, and tolerability. Patients should follow the dosage instructions provided by their healthcare professional.

Safety data for moxonidine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Moxonidine differs from drugs such as clonidine by selectively targeting imidazoline I1 receptors rather than α2‑adrenergic receptors, which may result in fewer sedative side effects. It is often used when a central‑acting agent is needed but a lower incidence of dry mouth and sedation is desired.

Moxonidin Ratiopharm should be stored at room temperature, below 25 °C, in the original packaging. Protect the tablets from moisture and direct sunlight to maintain product stability.

The medication is supplied as oral tablets and should be swallowed whole with a glass of water. It is usually taken once daily, but the exact timing and frequency are determined by the prescribing physician.

Serious adverse events, although rare, include severe hypotension, marked bradycardia, hepatic dysfunction, and allergic reactions such as rash or swelling. Patients should seek immediate medical attention if they experience any of these symptoms.

Moxonidin Ratiopharm is contraindicated in patients with severe hypotension, advanced heart block, or known hypersensitivity to moxonidine. Caution is also advised for individuals with significant renal or hepatic impairment.